Recently, researchers at the Norwegian University of Science and Technology’s Department of Neuroscience examined data collected from more than 130,000 Americans in the National Survey on Drug Use and Health, in an effort to determine what kind of effect psychedelics have on mental health.
A 2012 study funded by the National Institute of Health found that in addition to relieving the symptoms of AIDS (acquired immune deficiency syndrome), activation of the body’s cannabinoid receptors – something which cannabis does naturally – can actually combat its infection.
The study – which was conducted by researchers at George Mason University – found that; “the clinical use of CB2R agonists in the treatment of AIDS symptoms may also exert beneficial adjunctive antiviral effects against CXCR4-tropic viruses in late stages of HIV-1 infection.”
A new study published by the American Journal of Addiction, and funded in part by the National Institute of Health has found that THC – one of the primary components of cannabis – is “significantly associated with shorter sleep latency”, as well as “less difficulty falling asleep”.
For the study, “Thirteen male chronic daily cannabis smokers were administered oral THC doses (20 mg) around-the-clock for 7 days (40–120 mg daily) starting the afternoon after admission.”
A new study published in the annual journal Evidence-Based Complementary and Alternative Medicine has found that cannabis consumption leads to a “significant improvement” in “all cancer or anti-cancer treatment-related symptoms”.
According to researchers, “Cancer patients using cannabis report better influence from the plant extract than from synthetic products. However, almost all the research conducted to date has been performed with synthetic products”.
A new study being published in the October issue of the journal Progress in Neuro-Psychopharmacology and Biological Psychiatry has found that cannabinoids – compounds found in cannabis – can help to improve muscle rigidity (a “freezing” of the muscles), one of the primary symptoms of Parkinson’s disease, and may slow the progression of the disease.
A new study published by the British Journal of Pharmacology has found that cannabis can stop seizures due to its “significant anticonvulsant effects”.
For the study researchers used an extract made from the whole cannabis plant, and used the substance on a number of animal models – using rats and mice – and found that the extract was able to effectively stop seizures.
A new government funded study published in the journal Psychiatry Research has found that heavy cannabis use leads to better emotional memory and brain function in those with schizophrenia.
For the study – which was conducted at the Department of Psychiatry at the University of Montreal – researchers performed a magnetic resonance imaging study of emotional memory in patients with schizophrenia and cannabis abuse.
A new study funded by the National Institute for Translational Medicine, and published in last month’s issue of the journal Molecular Neurobiology, has found that cannabis may treat, as well as reverse the symptoms of neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
According to researchers; “Our findings support the potential of cannabidiol in reversing cognitive decline and its clinical use in treating neurodegenerative disorders such as Parkinson’s Disease and Alzheimer’s Disease.”
A new study published in the journal Environmental Toxicology and Pharmacology has found that cannabidiol – a compound of cannabis – may protect the heart from the dangerous side effects associated with the popular cancer drug doxorubicin.
For the study, the “potential protective effect of cannabidiol, the major non-psychotropic Cannabis constituent, was investigated against doxorubicin cardiotoxicity in rats.”
A new study published by the journal Neuropharmacology has found that cannabinoids may reduce aggression, and improve social interactions.
For the study, researchers “examined the role of cannabinoid CB1 receptors (CB1r) in aggressive behavior”, and found that a compound meant to mimic THC (a prime compound of cannabis) “significantly decreased the aggression levels” of the mice that it was administered to. The researchers also examined mice which were bred without CB1 receptors, and found them to be more inherently aggressive than normal mice.